ArticleAbdominal radiology (New York)2026
Radioembolization of primary liver tumors for patients with pre-existing ascites: beyond Child-Pugh score.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluates baseline characteristics associated with worsening ascites following TARE focusing on evaluation of the pre-existing ascites as a risk factor. A secondary objective was to examine survival among patients who developed ascites after TARE.
methodsA total of 288 TARE deliveries (237 patients) for primary liver tumors were retrospectively reviewed. Imaging before and six months after TARE was assessed for ascites. Tumor volume, treated area, delivered activity, and liver function tests and underlying etiology of liver disease were reviewed. Logistic regression was performed for risk factors of liver decompensation including pre-existing ascites as a risk factor. Survival curves were plotted for overall survival.
resultsMean (SD) age was 66 (11). 204 were male (71%). Median follow-up was 12.3 months (IQR 5.5-23.5). Of 288 tumors, 266 (92%) were HCC, 11 (4%) IHC, and 11 (4%) biphenotypic. 60 (of 288, 21%) patients had pre-existing ascites. New/worsening ascites occurred in 121 (of 288, 42%) [93 (77%) new, 28 (23%) worsening]. Patients with new/worsening ascites had significantly greater increases in bilirubin (p = 0.01, p < 0.001). In multivariable regression analysis pre-existing ascites was not associated with increased risk of post-TARE ascites progression, but a higher ALBI grade (OR = 2.87, p < 0.001) and baseline liver cirrhosis (OR = 2.64, p = 0.007) were associated with ascites after TARE. Neither perfused volume nor activity delivered predicted new/worsening ascites. Child-Pugh class (HR = 2.3, p < 0.001), pre-existing ascites (HR = 2, p < 0.001), ALBI score (HR = 1.5, p < 0.011) and new/worsening ascites (HR = 2.1, p < 0.001) were associated with lower survival.
conclusionsPre-existing ascites is associated with worse survival but should not preclude TARE. ALBI scoring can help distinguish patients at higher risk of post-TARE ascites.
Indexed as
Identifiers
41379141What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.